Literature DB >> 27633921

Use of Extracorporeal Support in Hemophagocytic Lymphohistiocytosis Secondary to Ehrlichiosis.

Amy Cheng1, Feifei Williams2,3, James Fortenberry2,3, Catherine Preissig4, Steven Salinas5, Pradip Kamat2,3.   

Abstract

Ehrlichiosis, caused by transmission of Ehrlichia chaffeensis to humans through the bite of an infected lone star tick, can lead to secondary hemophagocytic lymphohistiocytosis (HLH), a life-threatening condition caused by uncontrolled activation of the cellular immune system. We describe a child with HLH secondary to ehrlichiosis who developed multiorgan failure and was successfully managed with extracorporeal membrane oxygenation (ECMO). A 9-year-old boy developed headaches, fever, and sore throat after suspected tick exposure. He presented with pancytopenia, elevated ferritin, and soluble interleukin-2 receptor levels, all consistent with HLH. Bone marrow biopsy revealed hemophagocytosis. Polymerase chain reaction was positive for E chaffeensis He developed acute kidney injury, coagulation failure, hepatic insufficiency, and progressive respiratory failure requiring intubation. Due to refractory hypoxemia, he was cannulated for veno-venous ECMO. Continuous veno-venous hemofiltration was used to manage acute kidney injury and fluid overload. He received doxycycline and dexamethasone/etoposide for treatment of ehrlichiosis and HLH, respectively. Plasma exchange was used for thrombocytopenia-associated multiple organ failure. The patient was decannulated after 140 hours of ECMO and subsequently transferred for inpatient rehabilitation after extubation. Review of the Extracorporeal Life Support Organization Registry database identified 6 patients with tickborne diseases who received ECMO for organ support (survival in 3 of 6); ehrlichiosis was not reported in any of these cases. ECMO likely allowed a platform for stabilization and additional therapeutic interventions in this patient.
Copyright © 2016 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27633921     DOI: 10.1542/peds.2015-4176

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  2 in total

1.  Adjustments to pharmacologic therapies for hemophagocytic lymphohistiocytosis while on extracorporeal support.

Authors:  Angela C Weyand; Ryan P Barbaro; Kelly J Walkovich; David G Frame
Journal:  Pediatr Blood Cancer       Date:  2021-03-10       Impact factor: 3.838

2.  Prognostic death factors in secondary hemophagocytic lymphohistiocytosis children with multiple organ dysfunction syndrome receiving continuous renal replacement therapy: A multicenter prospective nested case-control study.

Authors:  Yun Cui; Jingyi Shi; Guoping Lu; Ying Wang; Xiaodong Zhu; Hong Ren; Yueniu Zhu; Gangfeng Yan; Chunxia Wang; Yucai Zhang
Journal:  Ther Apher Dial       Date:  2021-12-22       Impact factor: 2.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.